Avidity Biosciences (RNA) Competitors $32.01 -1.61 (-4.79%) Closing price 06/11/2025 04:00 PM EasternExtended Trading$32.90 +0.89 (+2.78%) As of 06/11/2025 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock RNA vs. ITCI, GMAB, SMMT, RDY, ASND, MRNA, VTRS, QGEN, BPMC, and ROIVShould you be buying Avidity Biosciences stock or one of its competitors? The main competitors of Avidity Biosciences include Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Summit Therapeutics (SMMT), Dr. Reddy's Laboratories (RDY), Ascendis Pharma A/S (ASND), Moderna (MRNA), Viatris (VTRS), Qiagen (QGEN), Blueprint Medicines (BPMC), and Roivant Sciences (ROIV). These companies are all part of the "pharmaceutical products" industry. Avidity Biosciences vs. Its Competitors Intra-Cellular Therapies Genmab A/S Summit Therapeutics Dr. Reddy's Laboratories Ascendis Pharma A/S Moderna Viatris Qiagen Blueprint Medicines Roivant Sciences Intra-Cellular Therapies (NASDAQ:ITCI) and Avidity Biosciences (NASDAQ:RNA) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, community ranking, profitability, earnings, risk, media sentiment, institutional ownership and valuation. Does the media favor ITCI or RNA? In the previous week, Avidity Biosciences had 34 more articles in the media than Intra-Cellular Therapies. MarketBeat recorded 34 mentions for Avidity Biosciences and 0 mentions for Intra-Cellular Therapies. Avidity Biosciences' average media sentiment score of 0.85 beat Intra-Cellular Therapies' score of 0.00 indicating that Avidity Biosciences is being referred to more favorably in the news media. Company Overall Sentiment Intra-Cellular Therapies Neutral Avidity Biosciences Positive Is ITCI or RNA more profitable? Intra-Cellular Therapies has a net margin of -14.07% compared to Avidity Biosciences' net margin of -2,772.45%. Intra-Cellular Therapies' return on equity of -9.93% beat Avidity Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Intra-Cellular Therapies-14.07% -9.93% -8.38% Avidity Biosciences -2,772.45%-27.66%-24.56% Which has more risk & volatility, ITCI or RNA? Intra-Cellular Therapies has a beta of 0.69, indicating that its share price is 31% less volatile than the S&P 500. Comparatively, Avidity Biosciences has a beta of 0.95, indicating that its share price is 5% less volatile than the S&P 500. Do analysts recommend ITCI or RNA? Intra-Cellular Therapies presently has a consensus price target of $109.70, indicating a potential downside of 16.81%. Avidity Biosciences has a consensus price target of $67.33, indicating a potential upside of 110.35%. Given Avidity Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Avidity Biosciences is more favorable than Intra-Cellular Therapies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Intra-Cellular Therapies 0 Sell rating(s) 10 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.17Avidity Biosciences 0 Sell rating(s) 0 Hold rating(s) 14 Buy rating(s) 1 Strong Buy rating(s) 3.07 Does the MarketBeat Community prefer ITCI or RNA? Intra-Cellular Therapies received 346 more outperform votes than Avidity Biosciences when rated by MarketBeat users. However, 70.12% of users gave Avidity Biosciences an outperform vote while only 65.74% of users gave Intra-Cellular Therapies an outperform vote. CompanyUnderperformOutperformIntra-Cellular TherapiesOutperform Votes52265.74% Underperform Votes27234.26% Avidity BiosciencesOutperform Votes17670.12% Underperform Votes7529.88% Do insiders and institutionals hold more shares of ITCI or RNA? 92.3% of Intra-Cellular Therapies shares are held by institutional investors. 2.6% of Intra-Cellular Therapies shares are held by insiders. Comparatively, 3.8% of Avidity Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Which has preferable earnings & valuation, ITCI or RNA? Intra-Cellular Therapies has higher revenue and earnings than Avidity Biosciences. Intra-Cellular Therapies is trading at a lower price-to-earnings ratio than Avidity Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIntra-Cellular Therapies$680.50M20.64-$139.67M-$0.73-180.64Avidity Biosciences$8.93M432.15-$212.22M-$3.00-10.67 SummaryAvidity Biosciences beats Intra-Cellular Therapies on 11 of the 19 factors compared between the two stocks. Get Avidity Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for RNA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RNA vs. The Competition Export to ExcelMetricAvidity BiosciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.86B$6.85B$5.57B$8.62BDividend YieldN/A2.56%5.28%4.18%P/E Ratio-11.118.7827.1720.06Price / Sales432.15255.64409.72157.10Price / CashN/A65.8538.2534.64Price / Book4.746.557.064.70Net Income-$212.22M$143.93M$3.23B$247.88M7 Day Performance-10.06%3.97%2.89%2.66%1 Month Performance9.14%11.32%9.06%6.40%1 Year Performance-16.55%4.20%31.40%14.07% Avidity Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RNAAvidity Biosciences2.2694 of 5 stars$32.01-4.8%$67.33+110.4%+10.7%$3.86B$8.93M-11.11190Trending NewsAnalyst ForecastAnalyst RevisionITCIIntra-Cellular Therapies0.9353 of 5 stars$131.87flat$109.70-16.8%N/A$14.05B$680.50M-151.57560GMABGenmab A/S3.7507 of 5 stars$21.77+3.9%$39.17+79.9%-17.2%$13.96B$3.12B12.511,660Positive NewsGap UpSMMTSummit Therapeutics2.9648 of 5 stars$17.73-2.7%$37.40+110.9%+159.7%$13.17B$700K-63.32110Trending NewsAnalyst ForecastAnalyst RevisionGap DownHigh Trading VolumeRDYDr. Reddy's Laboratories1.4815 of 5 stars$14.73+0.0%$17.00+15.4%+10.6%$12.29B$325.54B23.4524,800ASNDAscendis Pharma A/S3.5555 of 5 stars$175.69+7.9%$216.07+23.0%+30.2%$10.71B$368.70M-24.75640Positive NewsAnalyst ForecastAnalyst RevisionMRNAModerna4.5173 of 5 stars$27.05+1.8%$53.58+98.1%-81.3%$10.46B$3.14B-2.913,900Trending NewsVTRSViatris2.508 of 5 stars$8.69-1.1%$10.50+20.8%-15.6%$10.20B$14.33B-11.7437,000QGENQiagen3.1834 of 5 stars$44.89-0.5%$48.42+7.9%+9.2%$9.98B$2.00B125.006,030BPMCBlueprint Medicines1.1811 of 5 stars$127.79+26.1%$125.69-1.6%+21.4%$8.25B$562.12M-118.32640High Trading VolumeROIVRoivant Sciences2.3781 of 5 stars$11.17+1.6%$17.50+56.7%+6.7%$7.97B$29.05M-74.46860 Related Companies and Tools Related Companies Intra-Cellular Therapies Competitors Genmab A/S Competitors Summit Therapeutics Competitors Dr. Reddy's Laboratories Competitors Ascendis Pharma A/S Competitors Moderna Competitors Viatris Competitors Qiagen Competitors Blueprint Medicines Competitors Roivant Sciences Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RNA) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump Makes Major Crypto AnnouncementPay close attention to what I'm about to share… Most investors think Trump's pro-crypto policies will lift ...Crypto 101 Media | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredMarch 16th -- America’s most important day?50-Year Legend: Here's The Day Stocks Likely Crash Legendary quant analyst Marc Chaikin says in 50 years on...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avidity Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Avidity Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
